Valuation: Alumis Inc.

Market Cap 927M 815M 771M 699M 1.31B 88.96B 1.32B 9.23B 3.56B 45.39B 3.48B 3.4B 146B P/E 2026 *
-2.19x
P/E 2027 * -2.54x
Enterprise Value 211M 185M 175M 159M 299M 20.23B 300M 2.1B 811M 10.32B 791M 774M 33.17B EV / Sales 2026 *
33.7x
EV / Sales 2027 * 17x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.85%
1 week-9.37%
Current month-67.17%
1 month-68.01%
3 months-72.88%
6 months-71.13%
Current year-26.64%
1 week 6.83
Extreme 6.83
8.08
1 month 6.83
Extreme 6.83
22.54
Current year 6.83
Extreme 6.83
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Director/Board Member 55 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26
Samsara BioCapital LLC
SellCompany -642,712 0.5207%
04/09/26 Other

Director

0 0%
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%-9.37%+76.79% - 927M
-0.37%-3.67%+57.21%+87.75% 71.81B
+1.54%+0.33%+40.41%+86.32% 60.06B
0.00%+1.61%+35.10%+17.20% 27.93B
-0.14%-2.75%-14.13%+356.79% 25.7B
+0.57%+1.10%+1.02%-2.89% 24.89B
+0.39%+1.67%+26.47%-7.62% 20.92B
-1.70%+0.43%+150.24%+323.16% 15.04B
+0.36%+2.01%+49.51%+160.70% 14.46B
+3.47%-3.88%-4.92%+515.14% 13.87B
Average +0.53%-2.30%+41.77%+170.73% 27.56B
Weighted average by Cap. +0.45%-1.94%+38.86%+128.27%

Financials

2026 *2027 *
Net sales 6.26M 5.51M 5.21M 4.72M 8.87M 601M 8.92M 62.35M 24.08M 307M 23.51M 23M 986M 24.33M 21.4M 20.24M 18.36M 34.47M 2.34B 34.67M 242M 93.59M 1.19B 91.36M 89.38M 3.83B
Net income -427M -376M -355M -322M -605M -41.02B -609M -4.25B -1.64B -20.93B -1.6B -1.57B -67.26B -409M -359M -340M -308M -579M -39.23B -582M -4.07B -1.57B -20.02B -1.53B -1.5B -64.32B
Net Debt -716M -630M -595M -540M -1.01B -68.73B -1.02B -7.13B -2.75B -35.07B -2.69B -2.63B -113B -514M -452M -427M -388M -728M -49.33B -732M -5.12B -1.98B -25.17B -1.93B -1.89B -80.89B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
28/09/26 $7.160 +0.85% 2,245,382
25/09/26 $7.100 -2.61% 1,723,962
24/09/26 $7.290 -2.02% 2,605,339
23/09/26 $7.440 -8.26% 2,694,970
22/09/26 $8.110 +2.66% 2,524,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.160USD
Average target price
32.12USD
Spread / Average Target
+348.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock